Mode
Text Size
Log in / Sign up
Phase 4 N=14 Randomized Treatment

Anesthesia for Pain After Ankle Fracture Surgery

Chronic Pain · Ankle Fracture Surgery · Regional Anesthesia

Enrolled (actual)
14
Serious AEs
0.0%
Results posted
Jul 2021
Primary outcome: Primary: Pain Score at 12 Months - Experimental Group vs. Control Group — 36.33; 44.00 units on a scale — p=0.1269

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Ropivacaine (Drug); Nerve block (Procedure)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University of Cincinnati
Primary completion
Nov 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
Pain Score at 12 Months - Experimental Group vs. Control Group
36.33; 44.00 0.1269
SECONDARY
Pain Score at 2 Weeks - Experimental Group vs. Control Group
16.22; 13.67 0.8808
SECONDARY
Pain Score at 3 Months - Experimental Group vs. Control Group
26.25; 35.71 0.0382 sig
SECONDARY
Pain Score at 6 Months - Experimental Group vs. Control Group
34.00; 37.67 0.4696
SECONDARY
Incidence of Chronic Ankle Pain Diagnoses - Experimental Group vs. Control Group
3; 6; 3; 0 0.1818

Summary

This pilot study will test the hypothesis that prolonged regional peripheral nerve block will reduce development of chronic pain in patients undergoing surgery for ankle fracture compared to standard of care. Subjects will be followed for one year.

Eligibility Criteria

Inclusion Criteria

  • Referred for surgery for open reduction and internal fixation for ankle fracture

Exclusion Criteria

  • Unable to give informed consent in English
  • Unable to complete surveys in English
  • Unable to understand instructions for using pump in English
  • Unavailable for followup
  • Polytrauma; undergoing other surgeries or having other orthopedic injuries related to the precipitating cause of the ankle fracture
  • Infection
  • Peripheral vascular disease
  • Diabetes
  • Currently undergoing chemotherapy
  • Pregnancy
  • Currently lactating
  • Heart disease or heart rhythm disorder or taking anti-arrhythmic drugs
  • Severe renal impairment (Class 3 or worse kidney disease)
  • Liver disease (cirrhosis or liver failure)
  • Prior allergic reaction to any type of local anesthetic
  • Taking therapeutic doses of anti-coagulants or anti-platelet therapy (prophylactic doses started because of hospital admission are not an exclusion)
  • Currently taking antidepressants or other psychiatric medications
  • Single shot local nerve block prior to surgery was ineffective
  • Selected for neuraxial anesthesia rather than general anesthesia for the open reduction surgery
  • Already receiving chronic analgesic therapy for a separate chronic pain condition
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02950558). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search